Chimeric Therapeutics (ASX:CHM) has announced that the University of Chicago Medicine is now open to enrolling patients in the Phase 1/2 multi-centre clinical trial for the CHM CDH17 cell therapy.
The trial (NCT06055439) is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal, gastric, and intestinal neuroendocrine cancers.
CHM CDH17 is a third-generation, novel CAR-T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastases in the most common gastrointestinal tumours.
Associate Professor Dan Olson will lead the University of Chicago Medicine trial site. His research focuses on developing new immunotherapy treatments for solid tumours, including CAR-T cell therapy. The university is also home to Professor Michael Bishop, a member of Chimeric's scientific advisory board.
"We are gaining momentum on the CHM CDH17 study and are delighted to welcome UChicago Medicine to the trial," said Chimeric CEO, Dr Rebecca McQualter. "Following five successful manufacturing runs of CHM CDH17, we've now seen three patients dosed across the Sarah Cannon and UPenn sites and look forward to bringing announcing further updates on progress as soon as we're able."
The Phase 1 portion of this study is expected to enrol 15 patients and lead to dose selection and expansion with indication-specific Phase 2 cohorts.
